Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1978 1
1981 1
1983 2
1985 1
1986 2
1988 1
1989 1
1992 1
1994 1
1995 1
1996 4
1997 2
1998 3
1999 2
2000 3
2001 5
2002 5
2003 3
2004 4
2005 1
2006 2
2007 6
2008 7
2009 4
2010 6
2011 14
2012 18
2013 22
2014 16
2015 15
2016 11
2017 15
2018 6
2019 8
2020 11
2021 7
2022 8
2023 11
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: sasada t. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: sasada t. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Wei F, et al. Among authors: sasada t. J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788. J Immunother Cancer. 2023. PMID: 37433717 Free PMC article.
Exhaustion of CAR T cells: potential causes and solutions.
Kouro T, Himuro H, Sasada T. Kouro T, et al. Among authors: sasada t. J Transl Med. 2022 May 23;20(1):239. doi: 10.1186/s12967-022-03442-3. J Transl Med. 2022. PMID: 35606821 Free PMC article. Review.
[Pulmonary dirofilariasis].
Takei D, Yamaki M, Noriyuki T, Takemoto Y, Kawashima M, Saitoh R, Sasada T, Yoshida M, Amano H, Fukuda T, Nakahara M, Masuda K. Takei D, et al. Among authors: sasada t. Kyobu Geka. 2015 Jan;68(1):76-9. Kyobu Geka. 2015. PMID: 25595164 Japanese.
Next-generation peptide vaccines for advanced cancer.
Yamada A, Sasada T, Noguchi M, Itoh K. Yamada A, et al. Among authors: sasada t. Cancer Sci. 2013 Jan;104(1):15-21. doi: 10.1111/cas.12050. Epub 2012 Dec 4. Cancer Sci. 2013. PMID: 23107418 Free PMC article. Review.
214 results